Emerson CEO David Farr has announced that the company will be conducting a comprehensive review of its businesses as it adapts to “a challenging geopolitical and economic landscape.” It was perhaps no coincidence that this announcement came close on the heels of reports that activist investor D.E. Shaw & Co. has built a stake in Emerson and will push for a breakup. The company’s current structure consists of two core businesses, an automation business perhaps best known in biopharma for industry leading solutions like DeltaV, Rosemount, Micromotion and others, and a commercial and residential business. Early speculation is that the automation business would likely be spun-off as a stand-alone business. Learn More